CLINICAL IMPACT OF COMBINING CONTINUOUS INTRAVENOUS SODIUM INFUSION WITH CRRT ON TREATMENT DURATION AND PROGNOSIS IN PATIENTS WITH AKI

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 


 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/d7730c724b37bf491f38dfe0b43760e0.pdf
CLINICAL IMPACT OF COMBINING CONTINUOUS INTRAVENOUS SODIUM INFUSION WITH CRRT ON TREATMENT DURATION AND PROGNOSIS IN PATIENTS WITH AKI

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Akinori
Yamaguchi
Akinori Yamaguchi ymgc@shinshu-u.ac.jp Shinshu University Hospital Department of Nephrology Matsumoto Japan * Shinshu University Hospital Intensive Care Unit Matsumoto Japan
Atsuyoshi Mita mita@shinshu-u.ac.jp Shinshu University Hospital Intensive Care Unit Matsumoto Japan -
Kosuke Sonoda sonoda@shinshu-u.ac.jp Shinshu University Hospital Department of Nephrology Matsumoto Japan - Shinshu University Hospital Intensive Care Unit Matsumoto Japan
Koji Hashimoto khashi@shinshu-u.ac.jp Shinshu University Hospital Department of Nephrology Matsumoto Japan -
Yuji Kamijo yujibeat@shinshu-u.ac.jp Shinshu University Hospital Department of Nephrology Matsumoto Japan -
 
 
 
 
 
 
 
 
 
 

In patients with acute kidney injury (AKI) requiring renal replacement therapy, a multimodal approach utilizing various dialysis techniques, including high-sodium dialysate, has been reported to effectively stabilize hemodynamics and facilitate mechanical fluid removal. We previously reported that combining continuous renal replacement therapy (CRRT) with continuous intravenous sodium infusion (cIVNa), instead of using high-sodium dialysate, can stabilize hemodynamics and improve patient outcomes. In this study, we investigated the effects of cIVNa combined with CRRT on treatment duration and prognosis.

This retrospective study included 92 patients with prerenal AKI who underwent CRRT in the intensive care unit of Shinshu University Hospital between 2018 and 2022. Patients were divided into two groups: the control group (CRRT alone) and the intervention group (CRRT combined with cIVNa). We compared 6-day mortality, CRRT withdrawal within 6 days, and continuation of CRRT for ≥7 days between the two groups. Additionally, we compared the prognosis of subgroups who continued CRRT for ≥7, ≥14, and ≥28 days between the two groups. “CRRT withdrawal” is defined as survival for more than 7 days without the need for CRRT after its discontinuation.

There were no significant differences between the control and intervention groups in 6-day mortality (18% vs. 9%), CRRT withdrawal within 6 days (33% vs. 40%), or CRRT continuation for ≥7 days (49% vs. 51%). Among the subgroup who continued CRRT for ≥7 days (24 vs. 22 cases), baseline characteristics were largely similar, except for the serum sodium concentration at CRRT initiation, which was significantly higher in the intervention group (139 [135.75–147] vs. 148 [141.25–152.75], p = 0.023). In this subgroup, favorable trends in hemodynamic status and urine output were observed in the intervention group during the first 7 days, with some days showing statistically significant differences. Furthermore, the CRRT withdrawal rate was significantly higher in the intervention group compared to the control group (33% vs. 82%, p = 0.0012). The survival rate to hospital discharge was also higher in the intervention group (29% vs. 52%), although the difference did not reach statistical significance (p = 0.07). Among the subgroup who continued CRRT for ≥14 days (15 vs. 12 cases), the CRRT withdrawal rate remained significantly higher in the intervention group (20% vs. 67%, p = 0.02). The survival rate to hospital discharge was again higher in the intervention group (13% vs. 42%), but this difference was not statistically significant (p = 0.19). Among the subgroup who continued CRRT for ≥28 days (10 vs. 4 cases), both the CRRT withdrawal rate and survival to hospital discharge were higher in the intervention group (20% vs. 50%, p = 0.52 for both), though without statistical significance.

The combination of continuous intravenous sodium infusion with CRRT may improve CRRT withdrawal rates and contribute to better prognosis in patients requiring prolonged CRRT. Although trends toward improved survival were observed, further large-scale prospective studies are needed to confirm these findings.

Kewords